AbbVie (ABBV) and its partner in the trials, Roche (RHHBY), have cancelled five studies on an experimental leukemia and lymphoma medicine after two patient deaths said an AbbVie spokesperson, adding that AbbVie and its partner, Roche Holding, suspended the dose-escalation portion of the studies to determine the amount of drug that is safest and most effective, reported Bloomberg Friday afternoon.
The flap over Apple’s corporate tax strategy might sound like a snoozer, until you consider who makes up the difference …